arGEN-X BV has granted a worldwide exclusive license to RuiYi to develop and commercialize ARGX-109, a novel anti-IL-6 monoclonal antibody discovered and developed by arGEN-X. arGEN-X is backed by OrbiMed Advisors, Seventure Partners, Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB.
You are browsing the archive for LSP - peHUB.
arGEN-X, a biopharmaceutical company developing human monoclonal antibodies, has raised 27.5 million euro ($37 million) in Series B financing. OrbiMed Advisors and Seventure Partners co-led the round, which included participation from existing shareholders Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB. Mike Sheffery of OrbiMed will join the company’s board.
Sapiens Steering Brain Stimulation has secured a total of €10 million additional funding from the Wellcome Trust (UK), The Michael J. Fox Foundation (USA), and Agentschap NL (NL), to develop its Steering Brain Stimulation proposition to treat Parkinson’s disease and other brain disorders. These additional funds supplement an initial €13 million Series A funding round [...]